{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T23:10:20Z","timestamp":1776121820698,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.thromres.2026.109650","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:24:32Z","timestamp":1773188672000},"page":"109650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Patient characteristics, treatment patterns, and clinical outcomes in patients hospitalized with factor Xa inhibitor-associated major bleeds: A report from the REVERXaL study"],"prefix":"10.1016","volume":"260","author":[{"given":"Raza","family":"Alikhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Nour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Tiede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ofori-Asenso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hungta","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Yokobori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onivefu","family":"Odelade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooks D.","family":"Cash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Maegele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2026.109650_bb0005","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6707985","article-title":"Time trends and treatment pathways in prescribing individual oral anticoagulants in patients with nonvalvular atrial fibrillation: an observational study of more than three million patients from Europe and the United States","volume":"2022","author":"Vora","year":"2022","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.thromres.2026.109650_bb0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026863","article-title":"Prescribing trends of oral anticoagulants in US patients with cirrhosis and nonvalvular atrial fibrillation","volume":"12","author":"Simon","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2026.109650_bb0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","article-title":"Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review","volume":"40","author":"Ballestri","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.thromres.2026.109650_bb0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006703","article-title":"ENGAGE AF-TIMI 48 Investigators, Impact of spontaneous extracranial bleeding events on health state utility in patients with atrial fibrillation: results from the ENGAGE AF-TIMI 48 trial","volume":"6","author":"Wang","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2026.109650_bb0025","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jama.2017.21917","article-title":"Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality","volume":"319","author":"Inohara","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2026.109650_bb0030","article-title":"Clinical and health care resource use burden of hospitalizations for oral factor Xa inhibitor-associated major bleeding: a real-world analysis of Medicare beneficiaries","volume":"4","author":"Williams","year":"2023","journal-title":"J. Am. Coll. Emerg. Physicians Open"},{"key":"10.1016\/j.thromres.2026.109650_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajem.2023.07.042","article-title":"Real world utilization of andexanet alfa in the management of oral factor Xa inhibitor-associated gastrointestinal bleeding","volume":"73","author":"Brown","year":"2023","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.thromres.2026.109650_bb0040","doi-asserted-by":"crossref","first-page":"939","DOI":"10.5811\/WESTJEM.60587","article-title":"Treatment of factor-Xa inhibitor-associated bleeding with andexanet alfa or 4 factor PCC: a multicenter feasibility retrospective study","volume":"24","author":"Singer","year":"2023","journal-title":"West J. Emerg. Med."},{"key":"10.1016\/j.thromres.2026.109650_bb0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2023.06.021","article-title":"Hemostatic efficacy of four factor prothrombin complex concentrate in intracerebral hemorrhage patients receiving warfarin vs. factor Xa inhibitors","volume":"229","author":"Pon","year":"2023","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2026.109650_bb0050","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/phar.2925","article-title":"Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: a systematic review with meta-analysis","volume":"44","author":"White","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.thromres.2026.109650_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109046","article-title":"Design and rationale for REVERXaL: a real-world study of patients with factor Xa inhibitor-associated major bleeds","volume":"240","author":"Alikhan","year":"2024","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2026.109650_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/10760296211039020","article-title":"Retrospective comparison of andexanet alfa and 4-factor prothrombin complex for reversal of factor Xa-inhibitor related bleeding","volume":"27","author":"Stevens","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2026.109650_bb0065","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2026.109650_bb0070","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2026.109650_bb0075","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/rth2.12222","article-title":"Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017","volume":"3","author":"Lutsey","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109650_bb0080","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109650_bb0085","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109650_bb0090","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109650_bb0095","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109650_bb0100","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"The EINSTEIN Investigators","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109650_bb0105","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2026.109650_bb0110","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the anticoagulation forum","volume":"94","author":"Cuker","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2026.109650_bb0115","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/2396987319849763","article-title":"European Stroke Organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage","volume":"4","author":"Christensen","year":"2019","journal-title":"Eur. Stroke J."},{"key":"10.1016\/j.thromres.2026.109650_bb0120","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"Gomez-Outes","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2026.109650_bb0125","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3390\/jcm14031013","article-title":"Reversal of direct oral anticoagulants (DOACs) for critical bleeding or urgent procedures","volume":"14","author":"Goldin","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.thromres.2026.109650_bb0130","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/STROKEAHA.123.043033","article-title":"Code ICH: a call to action","volume":"55","author":"Li","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2026.109650_bb0135","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaneurol.2024.0221","article-title":"Time to anticoagulation reversal and outcomes after intracerebral hemorrhage","volume":"81","author":"Sheth","year":"2024","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.thromres.2026.109650_bb0140","article-title":"Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study","volume":"7","author":"Dobesh","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109650_bb0145","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2026.109650_bb0150","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor\u2013associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2026.109650_bb0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11239-020-02154-z","article-title":"Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products","volume":"51","author":"Castillo","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2026.109650_bb0160","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12028-020-00968-6","article-title":"Efficacy of 4-factor prothrombin complex concentrates in factor Xa inhibitor-associated intracranial bleeding","volume":"34","author":"Korobey","year":"2021","journal-title":"Neurocrit. Care"},{"key":"10.1016\/j.thromres.2026.109650_bb0165","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ajem.2022.02.029","article-title":"Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages","volume":"55","author":"Pham","year":"2022","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.thromres.2026.109650_bb0170","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/08971900221148034","article-title":"Hemostatic efficacy and safety of 4-factor prothrombin complex concentrate in DOAC-associated intracranial hemorrhage","volume":"37","author":"Whaley","year":"2024","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.thromres.2026.109650_bb0175","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0885066620916706","article-title":"Comparison of low- versus high-dose four-factor prothrombin complex concentrate (4F-PCC) for factor Xa inhibitor-associated bleeding: a retrospective study","volume":"36","author":"Wilsey","year":"2021","journal-title":"J. Intensive Care Med."},{"key":"10.1016\/j.thromres.2026.109650_bb0180","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11239-022-02752-z","article-title":"Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage","volume":"55","author":"Lipski","year":"2023","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2026.109650_bb0185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11239-023-02820-y","article-title":"Real-world clinical outcomes among US veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate","volume":"56","author":"Sutton","year":"2023","journal-title":"J. Thromb. Thrombolysis"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826000691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826000691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:36:35Z","timestamp":1776119795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384826000691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"alternative-id":["S0049384826000691"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109650","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient characteristics, treatment patterns, and clinical outcomes in patients hospitalized with factor Xa inhibitor-associated major bleeds: A report from the REVERXaL study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109650"}}